Researchers from Ocean University of China, Qingdao National Laboratory for Marine Science and Technology and affiliated organizations have reported the discovery of novel histone deacetylase 6 (HDAC6) inhibitors as potential anti-inflammatory agents.
Researchers from Italfarmaco SpA presented a new class of highly selective histone deacetylase 6 (HDAC6) inhibitors as potential candidates for the treatment of several pathologies, such as autoimmune disorders, neurodegenerative diseases, and cancer.
Eikonizo Therapeutics Inc. has identified histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders, among others.
